Data / Drug companies / Rentschler Biopharma Se
Rentschler Biopharma Se: 8 products in the FDA NDC directory, labeler code 64538
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Rentschler Biopharma Se (labeler code 64538) lists 8 products in the FDA National Drug Code Directory. By type: 8 bulk ingredients. Its main marketing category is bulk ingredients for compounding. The newest product started marketing on May 27, 2026.
The request: Watch Rentschler Biopharma Se (FDA labeler code 64538): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 64538
- Products in commercial distribution
- 8
- Packages
- 8
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- October 23, 2014
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Bulk ingredients for compounding | 5 | 62.5% |
| Bulk ingredients | 3 | 37.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Bulk ingredients | 8 | 100% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection | 3 | 37.5% |
| Injection, solution | 3 | 37.5% |
| Injection, powder, lyophilized, for solution | 2 | 25% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Pivekimab sunirine-pvzy | 64538-282 | Injection, powder, lyophilized, for solution | Bulk ingredients for compounding | May 27, 2026 |
| Ustekinumab-aauz | 64538-824 | Injection | Bulk ingredients | February 22, 2024 |
| Bimzelx | 64538-780 | Injection, solution | Bulk ingredients for compounding | October 17, 2023 |
| Epcoritamab-bysp | 64538-002 | Injection | Bulk ingredients | May 19, 2023 |
| Velmanase alfa-tycv | 64538-180 | Injection, powder, lyophilized, for solution | Bulk ingredients | March 1, 2023 |
| Lanadelumab-flyo | 64538-644 | Injection, solution | Bulk ingredients for compounding | August 24, 2018 |
| Mepsevii | 64538-001 | Injection | Bulk ingredients for compounding | November 15, 2017 |
| Antihemophilic factor (recombinant), porcine sequence | 64538-500 | Injection, solution | Bulk ingredients for compounding | October 23, 2014 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.